NCT06731153View on ClinicalTrials.gov

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions
Triple Negative Breast Cancer (TNBC)Metastatic Breast Cancer
Interventions
DRUG

Ivarmacitinib

a selective Janus kinase 1 inhibitor

DRUG

Camrelizumab (SHR-1210)

a humanised anti-programmed death-1 (anti PD-1) antibody

DRUG

Eribulin

Eribulin is an anticancer drug approved for treatment of metastatic breast cancer. This drug is a synthetic derivative from Japanese marine sponge Halichondria okadai. It acts by interfering with the microtubular growth ultimately leading to apoptosis after prolonged mitotic blockage.

Trial Locations (1)

200032

Breast cancer institute of Fudan University Cancer Hospital, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER